

Press release 29 December 2017

## **Conversion notice in BrainCool AB (publ)**

### **Conversion notice of convertible Notes, as part of the financing agreement announced 23 November 2017**

On December 27, 2017, BrainCool AB received a conversion notice for 15 Notes. The number of outstanding convertible notes under the first Tranche for future conversion is 155. The number of shares and the number of votes before the conversion notice was 34 269 401.

The number of issued shares remains unchanged as BrainCool has decided to settle the conversion of these 15 Notes in cash. The investor is entitled to receive in cash an amount equal to the number of new shares that should have been issued upon this conversion (such being 226 586) multiplied by the closing price of the BrainCool share on AktieTorget on 27 December 2017.

For terms and conditions of the convertible Notes, please visit:

<http://www.braincool.se/investor-relations-2/>

### **For more information**

Martin Waleij - CEO  
+46 - 733 -93 70 76  
E-mail: martin.waleij@braincool.se

### **About BrainCool AB (publ)**

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management.

BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on AktieTorget.

*This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on December 29, 2017.*